Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study-Reference-Cited by-同舟云学术

Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study

Published:2024-04 Issue:4 Volume:13 Page:891-906
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Schneider Stefan,Blick Gary,Burke Christina,Ward Douglas,Benson Paul,Felizarta Franco,Green Dallas,Donovan Cynthia,Harper Gavin,Merrill Deanna,Metzner Aimee A.,Mycock Katie,Wallis Hannah,Patarroyo Jimena,Brogan Andrew P.,Oglesby Alan^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40121-024-00961-y.pdf

Reference27 articles.

1. Back D. 2-Drug regimens in HIV treatment: pharmacological considerations. Germs. 2017;7:113–4.

2. Katlama C, Ghosn J, Murphy RL. Individualized antiretroviral therapeutic approaches: less can be more. AIDS. 2017;31:1065–71.

3. Cento V, Perno CF. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naive, virologically-suppressed patients: latest evidence from the literature on their efficacy and safety. J Glob Antimicrob Resist. 2020;20:228–37.

4. Girouard MP, Sax PE, Parker RA, et al. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clin Infect Dis. 2016;62:784–91.

5. Juluca [prescribing information]. Durham: ViiV Healthcare; 2022.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses;Infectious Diseases and Therapy;2024-04